Form 4: Major Shareholder Sells 3 Million Shares of Stoke Therapeutics Stock

Skorpios Trust, a 10% owner and director of Stoke Therapeutics, Inc. (STOK), has reported the sale of 3,000,000 shares of common stock at $10.20 per share.

Summary

• Skorpios Trust, identified as a 10% owner and director of Stoke Therapeutics, Inc. (STOK), disposed of 3,000,000 shares of common stock.
• The transaction occurred on June 4, 2025, at a price of $10.20 per share.
• Following this sale, Skorpios Trust, through its indirect holdings, beneficially owns 3,906,181 shares of Stoke Therapeutics common stock.
• The shares are indirectly held through Blue Horizon Enterprise Ltd. (2,967,621 shares) and Ezbon International Limited (938,560 shares), both solely owned by Skorpios Trust.
• Montrago Trustees Limited acts as the corporate trustee of Skorpios Trust.

Sentiment

Score: 3

Explanation: The sale of a significant number of shares by a 10% owner and director typically signals a negative sentiment or at least a lack of strong positive conviction from the selling party, potentially indicating a belief that the stock is fully valued or that better opportunities exist elsewhere.

Negatives

• A significant sale of 3,000,000 shares by a 10% owner and director, Skorpios Trust, indicates a substantial reduction in their stake.
• The sale of a large block of shares by an insider can be perceived negatively by the market, potentially signaling a lack of confidence in the company's future prospects or that the stock is fully valued.

Risks

• Potential negative market perception due to a large insider sale, which could signal a lack of confidence in future performance by a significant shareholder.
• Increased supply of shares in the market from the sale could put downward pressure on the stock price.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This document reports a specific insider transaction and does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: May interpret the large insider sale negatively, potentially leading to a decrease in share price due to perceived lack of confidence or increased supply.

Key Dates

Recommendation

Keywords

Stoke Therapeutics, STOK, SEC Form 4, Insider Trading, Share Sale, Beneficial Ownership, Skorpios Trust, 10% Owner, Director, Common Stock